Liver Involvement is Associated with Higher Risk of Rapidly Progressive Interstitial Lung Disease and Mortality in Anti-Melanoma Differentiation-Associated Gene 5 Antibody- Positive Dermatomyositis

References

• Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86. doi:10.1038/s41572-021-00321-x
   PubMedGoogle Scholar
• Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opinion Neurol. 2020;33(5):590–603. doi:10.1097/WCO.0000000000000855
   PubMed Web of Science ®Google Scholar
• Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–2200. doi:10.1002/art.24621
   PubMed Web of Science ®Google Scholar
• Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti-MDA5 Antibodies: bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol. 2021;12:773352. doi:10.3389/fimmu.2021.773352
   PubMed Web of Science ®Google Scholar
• Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous Ulceration in Dermatomyositis: association With Anti-Melanoma Differentiation-Associated Gene 5 Antibodies and Interstitial Lung Disease: analysis of Skin Ulcers in Dermatomyositis. Arthritis Care Res. 2015;67(5):667–672. doi:10.1002/acr.22498
   PubMed Web of Science ®Google Scholar
• Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024;20(1):48–62. doi:10.1038/s41584-023-01054-9
   PubMed Web of Science ®Google Scholar
• Wu W, Guo L, Fu Y, et al. Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clin Rev Allergy Immunol. 2021;60(2):293–304. doi:10.1007/s12016-020-08822-5
   PubMed Web of Science ®Google Scholar
• McPherson M, Economidou S, Liampas A, Zis P, Parperis K. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Semin Arthritis Rheumatism. 2022;53:151959. doi:10.1016/j.semarthrit.2022.151959
   PubMed Web of Science ®Google Scholar
• Jiang Y, Liu Y, Zhao Y, et al. Mitochondrial morphology and MAVS‐IFN1 signaling pathway in muscles of anti‐MDA5 dermatomyositis. Ann Clin Transl Neurol. 2021;8(3):677–686. doi:10.1002/acn3.51311
   PubMed Web of Science ®Google Scholar
• Nagashima T, Kamata Y, Iwamoto M, Okazaki H, Fukushima N, Minota S. Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. Rheumatol Int. 2019;39(5):901–909. doi:10.1007/s00296-019-04255-2
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713–1719. doi:10.1093/rheumatology/keq149
   PubMed Web of Science ®Google Scholar
• Opinc AH, Makowska JS. Antisynthetase syndrome – much more than just a myopathy. Semin Arthritis Rheumatism. 2021;51(1):72–83. doi:10.1016/j.semarthrit.2020.09.020
   PubMed Web of Science ®Google Scholar
• Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37(1):100–109. doi:10.1590/S1806-37132011000100015
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and Dermatomyositis: (Second of Two Parts). N Engl J Med. 1975;292(8):403–407. doi:10.1056/NEJM197502202920807
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and Dermatomyositis: (First of Two Parts). N Engl J Med. 1975;292(7):344–347. doi:10.1056/NEJM197502132920706
   PubMed Web of Science ®Google Scholar
• Mammen AL, Allenbach Y, Stenzel W, et al. 239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscul Disord. 2020;30(1):70–92. doi:10.1016/j.nmd.2019.10.005
   PubMed Web of Science ®Google Scholar
• Patel J, Ravishankar A, Maddukuri S, Vazquez T, Grinnell M, Werth VP. Identification of Similarities Between Skin Lesions in Patients With Antisynthetase Syndrome and Skin Lesions in Patients With Dermatomyositis by Highly Multiplexed Imaging Mass Cytometry. Arthritis Rheumatol. 2022;74(5):882–891. doi:10.1002/art.42050
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95(1):e70–e78. doi:10.1212/WNL.0000000000009727
   PubMed Web of Science ®Google Scholar
• Leise MD, Poterucha JJ, Talwalkar JA. Drug-Induced Liver Injury. Mayo Clin Proc. 2014;89(1):95–106. doi:10.1016/j.mayocp.2013.09.016
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Di Cola I, Di Muzio C, et al. Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Autoimmunity Rev. 2022;21(7):103114. doi:10.1016/j.autrev.2022.103114
   PubMed Web of Science ®Google Scholar
• Gono T, Miyake K, Kawaguchi Y, Kaneko H, Shinozaki M, Yamanaka H. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology. 2012;51(7):1336–1338. doi:10.1093/rheumatology/kes012
   PubMed Web of Science ®Google Scholar
• Horiike Y, Suzuki Y, Fujisawa T, et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology. 2019;58(12):2143–2152. doi:10.1093/rheumatology/kez185
   PubMed Web of Science ®Google Scholar
• Kawasumi H, Katsumata Y, Nishino A, et al. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody–positive Cases. J Rheumatol. 2018;45(7):947–955. doi:10.3899/jrheum.170997
   PubMed Web of Science ®Google Scholar
• Peng QL, Zhang YM, Liang L, et al. A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. Clin Exp Immunol. 2020;199(3):314–325. doi:10.1111/cei.13404
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Hozumi H, Yasui H, et al. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease. J Rheumatol. 2019;46(8):935–942. doi:10.3899/jrheum.180825
   PubMed Web of Science ®Google Scholar
• Zuo Y, Ye L, Liu M, et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology. 2020;59(10):2829–2837. doi:10.1093/rheumatology/keaa034
   PubMed Web of Science ®Google Scholar
• Zhao S, Ma X, Zhang X, et al. Clinical significance of HScore and MS score comparison in the prognostic evaluation of anti-MDA5-positive patients with dermatomyositis and interstitial lung disease. Modern Rheumatol. 2022;32(2):373–379. doi:10.1093/mr/roab017
   PubMed Web of Science ®Google Scholar
• Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation–associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018;78(4):776–785. doi:10.1016/j.jaad.2017.12.010
   PubMed Web of Science ®Google Scholar
• Gono T, Okazaki Y, Kuwana M. Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology. 2021;keab371. doi:10.1093/rheumatology/keab371
   Google Scholar
• De Lorenzis E, Natalello G, Gigante L, Verardi L, Bosello SL, Gremese E. What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19? Autoimmunity Rev. 2020;19(11):102666. doi:10.1016/j.autrev.2020.102666
   PubMed Web of Science ®Google Scholar
• Wang G, Wang Q, Wang Y, et al. Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: a Retrospective Cohort Study. Front Immunol. 2021;12:791348. doi:10.3389/fimmu.2021.791348
   PubMed Web of Science ®Google Scholar
• Fukada A, Fujisawa T, Hozumi H, et al. Prognostic Role of Interferon‐λ3 in Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis‐Associated Interstitial Lung Disease. Arthritis Rheumatol. 2024:art.42785. doi:10.1002/art.42785
   PubMedGoogle Scholar
• Matsuda S, Kotani T, Ishida T, et al. Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease. Rheumatology. 2020;59(2):310–318. doi:10.1093/rheumatology/kez301
   PubMed Web of Science ®Google Scholar
• Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology. 2014;53(12):2196–2203. doi:10.1093/rheumatology/keu258
   PubMed Web of Science ®Google Scholar
• Shimizu T, Koga T, Furukawa K, et al. IL‐15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. J Intern Med. 2021;289(2):206–220. doi:10.1111/joim.13154
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhao L, Xiao Y, et al. The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies. Front Pharmacol. 2022;13:852055. doi:10.3389/fphar.2022.852055
   PubMed Web of Science ®Google Scholar
• Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14(5):279–289. doi:10.1038/nrrheum.2018.42
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation. 2021;59(6):709–740. doi:10.1016/j.resinv.2021.04.011
   PubMed Web of Science ®Google Scholar
• Tsuji H, Nakashima R, Hosono Y, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis. Arthritis Rheumatol. 2020;72(3):488–498. doi:10.1002/art.41105
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial. Respirology. 2021;26(4):370–377. doi:10.1111/resp.13978
   PubMed Web of Science ®Google Scholar
• Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology. 2015;54(1):39–44. doi:10.1093/rheumatology/keu166
   PubMed Web of Science ®Google Scholar
• Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology. 2020;59(5):1084–1093. doi:10.1093/rheumatology/kez394
   PubMed Web of Science ®Google Scholar
• Wang CR, Lin WC, Wong TW. Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease. ITT. 2023;12:187–192. doi:10.2147/ITT.S445971
   Google Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease. N Engl J Med. 2019;381(3):291–293. doi:10.1056/NEJMc1900045
   PubMed Web of Science ®Google Scholar
• Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology. 2018;57(12):2114–2119. doi:10.1093/rheumatology/key188
   PubMed Web of Science ®Google Scholar